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Insulin receptor tyrosine kinase substrate (IRTKS) has been demonstrated to be a scaffold protein
involved in plasma membrane deformation and actin cytoskeleton remodeling. IRTKS is tyrosine
phosphorylated in response to insulin stimulation. However, the mechanism and function of IRTKS
phosphorylation remains unclear. Here, we report that overexpression of IRTKS increases the speed
of wound closure of HT1080 cells in a Src-dependent manner. Active Src phosphorylates IRTKS
in vivo and in vitro. Deletion mapping and mutation analysis revealed that six tyrosine residues
(Y37, Y156, Y163, Y274, Y293 and Y439) were Src-stimulated phosphorylation sites on IRTKS. Disrup-
tion of Src-stimulated IRTKS phosphorylation abolished the effect of IRTKS on wound closure. Col-
lectively, these data suggest Src-stimulated IRTKS phosphorylation is essential for its function in cell
motility.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The IRSp53 family of proteins is involved in signal transduction
pathways that link actin remodeling and membrane protrusion
[1]. The IRSp53 family protein, insulin receptor tyrosine kinase sub-
strate (IRTKS), has a wide tissue distribution and has been charac-
terized as a substrate of insulin receptor tyrosine kinase [2]. IRTKS
contains an inverted Bin–amphipysin–Rvs167 (I-BAR) domain (also
known as IMD) in its N-terminus, a canonical Src homology 3 (SH3)
domain in its central region and aWW-binding (WWB) domain near
its C-terminus. I-BAR domain deforms the membranes into tubular
structures and induces plasma membrane protrusions, such as ﬁlo-
podia and microspikes [3–6]. Both the SH3 and WWB domains are
involved in protein interactions. The proteins associated with the
SH3 domain of IRTKS have not been characterized, but the SH3 do-
main of IRSp53 was shown to bind to N-WASP and other proteins
which are involved in actin polymerization and ﬁlopodia formation
[1,7]. A recent study demonstrated that the WWB domain is re-
quired for the association of IRSp53 with Eps8 [8].
Actin polymerization andmembrane deformation are important
processes for cell mobility [9]. IRSp53 family proteins contribute to
actin dynamics and the development of membrane protrusions for
generating ﬁlopodia [7,10]. While IRSp53 overexpression results
in the formation ofmany long, oftenwavy, ﬁlopodia-like extensions,
overexpression of IRTKS induces the formation of numerous actinchemical Societies. Published by E
Genome Center at Shanghai,
x: +86 21 50800402.
.microspikes at the cell periphery [2]. Filopodia and lamellipodia
have been shown to be important in the context of cell invasion
and metastasis [11]. Funato et al. [12] reported that inhibition of
association of the IRSp53/Eps8 complex suppressed motility and
invasiveness in HT1080 cells, suggesting that IRSp53 family pro-
teins could be involved in cell motility.
Both IRSp53 and IRTKS rapidly undergo tyrosine phosphoryla-
tion in insulin-treated cells [2,13]. Increased tyrosine phosphoryla-
tion of IRSp53 was also observed in cells expressing a transforming
chicken c-Src (mutant Phe-527), or in cells treated with insulin-like
growth factor-1 (IGF-1) or epidermal growth factor (EGF) [14,15]
Recent studies revealed that serine/threonine phosphorylation of
IRSp53 regulated IRSp53-dependent ﬁlopodial dynamics by pro-
moting the association of IRSp53 and 14-3-3 protein [16,17]. How-
ever, little is known about the mechanism and function of tyrosine
phosphorylation of IRTKS.
Src is the prototypic member of a family of non-receptor
membrane-associated tyrosine kinases [18]. The Src family of tyro-
sinekinases (SFKs) controlsmultiple cellular functions includingcell
proliferation, cell cycle progression, cell death, differentiation, adhe-
sion, migration and invasion [19]. Src is both a substrate and an up-
stream activator of receptor tyrosine kinases (RTKs), thereby
creating a positive-regulatory loop that contributes to the robust-
ness and persistence of RTK signaling [20]. During cell migration
and invasion, Src exerts a profound effect on the reorganization of
the cytoskeletonandonadhesion systems [21]. In this study, the role
of Src in IRTKS phosphorylation, the tyrosine residues involved in
Src-mediated phosphorylation of IRTKS and the effect of Src-stimu-
lated IRTKS phosphorylation on cell motility were investigated.lsevier B.V. All rights reserved.
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Fig. 1. IRTKS promotes the migration of HT1080 cells. (A) The inducible expression of IRTKS in tetracycline (Tet)-off stable HT1080 cells. HT1080-A8 cells were cultured in the
presence or absence of Tet. The expression of IRTKS was analyzed by western blotting. (B) IRTKS overexpression enhanced cell migration. HT1080-A8 cells were scraped with
micropipette tips. Images were acquired at 0, 12 and 24 h after wounding. The wound healing rates at 24 h after wounding are shown in (C). Values represent the mean ± S.D.
⁄P < 0.005, n = 8. (D) Depletion of Src inhibited IRTKS-enhanced cell migration. Src siRNA and control siRNA were transfected into HT1080-A8 cells. The cells were wounded at
24 h. Images were acquired at 0, 12 and 24 h after wounding. (E) HT1080-A8 cells treated with siSrc were collected and endogenous Src was analyzed by western blotting. (F)
Wound healing rate at 24 h after the wounding of HT1080-A8 cells treated with siSrc. Mean ± S.D. ⁄P < 0.001, ⁄⁄P > 0.5, n = 8.
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2.1. Plasmid, recombinant protein and antibody
Constitutively-active human c-Src (Y530F) was cloned into vec-
tor pCDNA-3.0, a kind gift from Dr. Daohong Lin (New York Medical
College, USA). The entire open reading frame of human IRTKS was
ampliﬁed from a human fetal liver cDNA library (Clontech) andsubcloned into mammalian cell expression vector pFLAG-CMV2
(Sigma) for mammalian expression [22]. IRTKS truncation and
internal mutation mutants were generated by PCR and site-
directed mutagenesis, respectively. IRTKS with FLAG tag was
constructed in pTet-splice expression vector for generating tetra-
cycline (Tet)-off stable cell lines. pGEX4T-1-IRTKS and pET-28a-
IRTKS were constructed to produce the GST–IRTKS and His–IRTKS
fusion proteins. The recombinant GST–IRTKS and His–IRTKS fusion
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Fig. 2. Src stimulates tyrosine phosphorylation of IRTKS. (A) Depletion of Src decreased IRTKS phosphorylation in HT1080 cells. HT1080 cells were transfected with siSrc and
control siRNA, and collected at 48 h. The endogenous IRTKS was immunoprecipitated. The tyrosine phosphorylation of IRTKS was analyzed with an anti-tyrosine antibody
(pY). (B) The endogenous phosphorylation of IRTKS was inhibited by the SFK-speciﬁc inhibitor PP2 in H1299 cells. Cells were treated with 10 lM PP2 for 4 h and IRTKS
phosphorylation was analyzed. (C) Active Src induced IRTKS phosphorylation. Constitutively active Src530F was overexpressed in U2OS cells and the phosphorylation of IRTKS
was analyzed. V: vector. (D) Src directly phosphorylated IRTKS in vitro. Active Src was puriﬁed from U2OS cells transfected with Src530F by immunoprecipitation with a Src
antibody and incubated with recombinant His-IRTKS protein in kinase buffer for 15 min. The supernatant and the immunoprecipitated beads were separated and analyzed by
western blotting. Tyrosine phosphorylation of IRTKS was detected in the supernatant (upper two panels). Src was detected in the precipitates (the third panel).
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AKTAxpress protein puriﬁer (GE Healthcare). Mouse monoclonal
anti-Src (Abgent), actin (Sigma) and phospho-tyrosine PT-100 (Cell
signaling technology) antibodies were used for western blotting.
Mouse monoclonal anti-Src antibody (Santa Cruz) was used for
immunoprecipitation. Rabbit polyclonal anti-IRTKS antibody was
raised against GST–IRTKS fusion protein and puriﬁed from antise-
rum with protein G sepharose beads (Roche).
2.2. Cell culture and transfection
U2OS and H1299 cells were cultured in RPMI 1640medium con-
taining 10% fetal calf serum. HT1080 cells were cultured in MEM
containing non-essential amino acids with 10% fetal calf serum.
For maintaining the IRTKS Tet-off HT1080-A8 cells, 0.5 lg/ml of
Tet was added to the culture medium. Cells were transfected using
FuGENE HD or FuGENE 6, according to the manufacturer’s protocol
(Roche). Short interfering RNA (siRNA) oligonucleotides were
transfected into cells using the transfection reagent Lipofectamine
2000 (Invitrogen). The Src siRNA (siSrc) sequence was 50-AAACU-
CCCCUUGCUCAUGUACTT-30, and the negative control siRNA (siNC)
sequence was 50-CUUACGCUGAGUACUUCGATT-30.
2.3. Generation of IRTKS Tet-off stable cell lines
pTet-splice-Flag-IRTKS together with pTet-Tak and the select-
able marker, pcDNA3.0, were transfected into HT1080 cells. The
IRTKS Tet-off expression clones were selected with neomycin.
The stable cell clones were cultured in the presence or absence
of Tet. The inducible expression of IRTKS was analyzed by western
blotting with anti-FLAG and anti-IRTKS antibodies.2.4. Wound healing assay
Cells were plated in 60-mm dishes at the same density, scratch-
wounded with a micropipette tip, washed to remove detached
cells, and then provided with fresh medium and incubated at
37 C during image acquisition. Wounds were marked with a felt
tip pen and images were acquired at these sites using a 5 objec-
tive at 0 h, and again after 12 or 24 h. The gap width was measured
by marking the wound width at each time point. The wound heal-
ing rate was calculated as follow: (gap width at 0 h – gap width at
24 h)/gap width at 0 h.
2.5. Immunoprecipitation and western blot analysis
The cells were treated with 0.5 mM sodium ortho-vanadate for
2 h before being lysed in lysis buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 0.5% Triton X-100, 0.5% Nonidet P-40, 0.5 mM sodium ortho-
vanadate and proteinase inhibitor), or boiled in denaturing lysis
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% SDS). The denaturing
lysates were diluted with dilution buffer (50 mM Tris pH 7.4,
150 mM NaCl, 1% Triton X-100) until the concentration of SDS
reached 0.2%. The immunoprecipitation assay was performed
according to a previously described protocol [23]. Brieﬂy, the cell ly-
sates were incubated with the indicated antibodies and protein G
sepharose beads at 4 C for 4 h or overnight. Each immunoprecipi-
tate was washed four times with lysis buffer and analyzed by wes-
tern blotting. Protein samples were resolved by SDS–PAGE and
transferred onto nitrocellulose membrane, which was blocked in
5% skim milk or 5% bovine serum albumin (BSA) in phosphate-buf-
fered saline containing Tween (PBS–Tween) and probed with the
indicated antibodies. The membrane was scanned using the
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Fig. 3. Multiple tyrosine phosphorylation sites exist on IRTKS. (A) Schematic illustrations of IRTKS and its truncated variants. The position of tyrosine residues and functional
domains are indicated. (B) Src induced multiple tyrosine phosphorylations in IRTKS. Flag-tagged full-length IRTKS and its truncated mutants were co-transfected with Src530F
or control plasmid. IRTKS variants were immunoprecipitated with anti-FLAG beads and analyzed with anti-pY and anti-IRTKS antibodies. Tyrosine phosphorylation of IRTKS
truncation mutants is indicated by an asterisk.
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wavelength.
2.6. In vitro kinase assay
U2OS cells were transfected with active Src530F and lysed in
lysis buffer (10 mM Tris pH 7.4, 1.0% Triton X-100, 0.5% Nonidet
P-40, 150 mM NaCl, 20 mM sodium ﬂuoride, 0.5 mM sodium
ortho-vanadate, 1.0 mM EDTA, 1.0 mM EGTA, 0.2 mM PMSF). Src
was immunoprecipitated with Src antibody and protein G sephar-
ose beads. Immunoprecipitated Src and 2.5 lg of puriﬁed His–
IRTKS fusion protein were incubated in 40 ll of kinase buffer
(10 mM Tris pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT,
50 lM ATP) at 37 C for 15 min. The reaction supernatant and pro-
tein G sepharose beads were then separated by centrifugation. The
supernatant was used to detect the phosphorylation of IRTKS. Src
protein precipitated with Src antibody and protein G sepharose
beads was also analyzed by western blotting.
3. Results and discussion
3.1. IRTKS enhances cell migration in a Src-dependent manner
To examine the role of IRTKS in cell motility, a stable HT1080
cell line, HT1080-A8, which expressed ectopic IRTKS upon with-
drawal of Tet (Fig. 1A), was used. HT1080-A8 cells or wild-type
HT1080 cells grew as monolayers in the presence or absence of
Tet. The cells were scratched and monitored for wound healingover time. As shown in Fig. S1, Tet could not alter the speed of
wound closure of wild-type HT1080 cells. However, the Tet-off
HT1080-A8 cells in which IRTKS was overexpressed migrated
markedly faster than the control cells (Fig. 1B). The wound healing
rate of HT1080-A8 cells was signiﬁcantly increased by the induc-
ible expression of IRTKS at 24 h (Fig. 1C, P < 0.001).
Recently, Liu et al. reported that IRSp53 inﬂuences v-Src-elicited
proliferation and tumorigenesis through the association between
IRSp53 and Eps8 [8], suggesting IRSp53 family proteins may partic-
ipate in Src signaling. Src plays a pivotal role in cell migration [21].
To explore whether Src also controls cell migration induced by
IRTKS, we depleted Src expression in HT1080-A8 cells by
introducing a siRNA for Src (Fig. 1E). Depletion of Src slightly de-
creased HT1080-A8 cell migration in the presence of Tet (Fig. 1D,
upper two panels; and Fig. 1F, ⁄⁄P > 0.5). However, in HT1080-A8
cells cultured in mediumwithout Tet, the increase in cell migration
induced by IRTKS overexpression was signiﬁcantly inhibited by
siSrc, suggesting that Src controls IRTKS-enhanced cell mobility
(Fig. 1D, lower two panels; and Fig. 1F, ⁄P < 0.001).
3.2. IRTKS is a substrate of Src
The protein tyrosine kinase Src catalyzes the transfer of the ter-
minal phosphate group of ATP to speciﬁc tyrosine residues present
on protein substrates, and thereby transfers signals downstream of
a variety of cell surface receptors, including integrins and RTKs [19].
A previous study reported that IRTKS could be phosphorylated upon
insulin stimulation [2]. We also found that EGF induces tyrosine
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2976 G. Chen et al. / FEBS Letters 585 (2011) 2972–2978phosphorylation of IRTKS (data not shown). Interestingly, IRTKS is
highly phosphorylated in some cells, including H1299, HT1080
and Hep3B cells, while phosphorylation of IRTKS was hardly de-
tected in U2OS and HeLa cells (Fig. S2). Our experiments revealed
that Src controls IRTKS-induced cell migration in HT1080 cells
which possess highly phosphorylated IRTKS, therefore, we tested
whether Src kinase activity inﬂuences IRTKS phosphorylation. In
HT1080 cells treated with Src siRNA, tyrosine phosphorylation of
IRTKS was signiﬁcantly decreased (Fig. 2A). Moreover, a speciﬁc
inhibitor of the Src family kinase, PP2, inhibited IRTKS phosphoryla-
tion in H1299 cells (Fig. 2B). When a construct expressing a consti-
tutively active Src mutant, Src530F, was transfected into U2OS cells,
phosphorylation of IRTKS was dramatically enhanced (Fig. 2C).
Taken together, these data indicated that active Src could induce
IRTKS phosphorylation in vivo. We then puriﬁed active Src from
U2OS cells transfected with Src530F and recombinant IRTKS protein
expressed in E. coli, and performed an in vitro kinase assay. The
results showed that Src could phosphorylate IRTKS in vitro
(Fig. 2D), suggesting that IRTKS is a direct substrate of Src.
3.3. Domain mapping of the tyrosine phosphorylation sites in IRTKS
We next analyzed the tyrosine residues of IRTKS required for
Src-induced phosphorylation. IRTKS contains 15 tyrosine residues,
most of which are located in its functional domains (Fig. 3A and
Fig. S3A). Point mutations of each individual tyrosine residue didnot abolish IRTKS phosphorylation (data not shown), suggesting
that IRTKS has multiple tyrosine phosphorylation sites. Previous
studies have characterized the sequence requirements for phos-
phorylation of IRSp53 in response to stimulation with insulin or
EGF. Okamura-Oho et al. [24] reported that the simultaneous
mutation of three tyrosine residues in the I-BAR domain (Y17,
Y115, Y178) abrogated IRSp53 phosphorylation induced by insulin
or IGF-1, suggesting that the phosphorylation of IRSp53 may occur
within the I-BAR domain. In another study, Heung et al.
demonstrated that tyrosine residues in the I-BAR domain were
not required for IRSp53 phosphorylation, and that tyrosine 310
in IRSp53 was the primary site of tyrosine phosphorylation in
response to insulin signaling [15]. Moreover, EGF receptor-induced
phosphorylation of IRSp53 has been shown to be distinct from that
of insulin receptor-induced phosphorylation, suggesting that
IRSp53 contains multiple phosphor-tyrosine sites [15].
To investigate the signiﬁcance of different domains or frag-
ments of IRTKS with respect to tyrosine phosphorylation, we gen-
erated IRTKS truncations (Fig. 3A). Interestingly, all truncated
fragments of IRTKS could be phosphorylated by Src (Fig. 3B), sug-
gesting that IRTKS contains multiple tyrosine phosphorylation
sites in its different regions. The IRTKS N-terminal truncation,
IRTKS-D1 which contains the whole I-BAR domain, and the IRTKS
C-terminal truncation, IRTKS-D5 which contains the SH3 domain
and the WWB domain, were used for further experiments to iden-
tify the phosphorylation sites on IRTKS induced by active Src.
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IRTKS
A group of IRTKS mutants containing single or double tyrosine-
to-phenylalanine mutations in the I-BAR domain were co-transfec-
ted with Src530F into U2OS cells. The phosphorylation levels of each
mutantwere semi-quantiﬁed by densitometric analysis (Fig. 4A and
Fig. S4). Five individual mutations (Y16F, Y37F, Y114F, Y156F and
Y163F) decreased the levels of IRTKS phosphorylation (Fig. 3A),
implying that these ﬁve tyrosine residues were involved in the
Src-induced phosphorylation of IRTKS. Consistent with this obser-
vation, a mutant (D1M5) containing the IRTKS-D1 truncation and
mutations in these ﬁve tyrosine residues was not phosphorylated
by active Src (Fig. 4B, lane 12). To deﬁne Src-induced phosphoryla-
tion of the individual tyrosine residues in the I-BARdomain,we gen-
erated single point recovery mutants of D1M5 (16R, 37R, 114R,
156R and 163R) by re-substituting phenylalanine with tyrosine.
Using these recovery mutants, we found that Y37, Y156 and Y163
were Src-induced tyrosine phosphorylation sites in the I-BAR do-
main of IRTKS (Fig. 4B, lanes 8, 10 and 16). Notably, all of these three
tyrosine residues were conserved among IRTKS and IRSp53
(Fig. S3A).
The same strategy was used to identify Src-stimulated tyrosine
phosphorylation sites of IRTKS in its C-terminal region. All ﬁve sin-
gle point mutations of tyrosine residues in the C-terminal region
decreased phosphorylation of the IRTKS-D5 truncation (Fig. 4C
and Fig. S5). D5M5, a mutant possessing an IRTKS-D5 truncation
and mutations in these ﬁve residues, was used to generate single
point recovery mutants (274R, 293R, 380R, 396R and 439R). Using
these recovery mutants, Y274, Y293 and Y439 were conﬁrmed as
three more tyrosine phosphorylation sites on IRTKS (Fig. 4D).
Two tyrosine residues (Y274 and Y293) were located in the region
between the I-BAR and SH3 domains of IRTKS, while Y439 was
located in the conserved WWB domain of IRTKS. (Fig. 3A and
Fig. S3A). In addition, Y274 of IRTKS was conserved with Y310 of
IRSp53, which had been demonstrated to be phosphorylated in
response to insulin stimulation (Fig. S3A).Next, phosphorylation of an IRTKS mutant, M6, in which six
tyrosine residues (Y37, Y156, Y164, Y274, Y293 and Y439) were
replaced with phenylalanine, was detected in U2OS cells with
Src530F expression. As expected, Src-induced IRTKS phosphoryla-
tion disappeared in this mutant (Fig. 4E). Thus, in total, six tyrosine
residues of IRTKS were identiﬁed as phospho-acceptors upon stim-
ulation of active Src.
3.5. IRTKS phosphorylation affects cell motility
The N-terminal I-BAR domain is the most conserved region
among proteins of the IRSp53 family [1,25]. I-BAR domain binds
to PI(4,5)P2-enriched membranes and induces membrane protru-
sions [4,5,26]. The I-BAR domains of IRSp53 and MIM form a zep-
pelin-shaped dimer and induce membrane evagination [3,10,27].
Each end of the dimeric I-BAR domain consists of relatively large
positively charged regions which are responsible for its binding
to the cell membrane [3,10]. The basic amino acids of this region
are conserved among IRSp53 and IRTKS (Fig. S2A). Interestingly,
Y156 and Y163 are also located at the end of IRTKS I-BAR domain,
close to these conserved basic residues (Fig. S3B). Phosphorylation
of Y156 and Y163 of IRTKS may regulate the binding of I-BAR do-
main to cells membrane and I-BAR domain induced membrane
protrusion. In addition, previous studies indicated that the
serine/threonine phosphorylations in the C-terminal region of
IRSp53 affect the association of IRSp53 with its binding proteins,
and regulate IRSp53-mediated ﬁlopodium formation and cell–
extracellular matrix signaling [16,17]. Therefore, phosphor-tyro-
sine in the IRTKS C-terminal region may also affect its protein
interactions and further regulate its function in cell motility.
To assess the effect of Src-stimulated IRTKS phosphorylation in
IRTKS-promoted cell migration, HT1080 cells were transiently
transfected with IRTKS, M6 or control plasmid, and used to perform
wound healing assays (Fig. 5A). While the wound healing rates of
cells with IRTKS overexpression increased markedly in comparison
with control cells, the IRTKS-M6 mutant did not show signiﬁcantly
enhanced cell migration (Fig. 5B). Tyrosine phosphorylation
2978 G. Chen et al. / FEBS Letters 585 (2011) 2972–2978analysis also showed that wild-type IRTKS was highly phosphory-
lated in HT1080 cells, whereas no phosphorylation could be de-
tected in the IRTKS-M6 mutant (Fig. 5C). These data suggested
that Src-stimulated IRTKS phosphorylation was essential for the
IRTKS-induced increase in cell mobility.
In summary, our results revealed that IRTKS is a substrate of Src
and promotes Src-dependent cell migration. Six tyrosine residues
of IRTKS, located in its functional domain for membrane interac-
tion (Y37, Y156, Y163 in I-BAR domain) and potentially involved
in regulating protein associations (Y439 in WWB and Y274, Y293
in the region between I-BAR and SH3 domain), were identiﬁed as
Src-stimulated tyrosine phosphorylation sites. We also provide
data that phosphorylation of IRTKS may contribute to cell motility.
The function of Src-stimulated IRTKS phosphorylation therefore
merits further investigation.
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